Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from ...

Business people in a boardroom engage in a creative discussion, exchanging ideas with a confident leader facilitating the meeting. The happy team represents successful collaboration and a modern tech ...

When you contemplate an investment in a mutual fund scheme, one of the key motivations for you could be its past returns over a few years. Although past returns do not guarantee returns in future, ...

Spoiler alert! The following contains details from Season 5, Episode 3 of "Stranger Things," "The Turnbow Trap." These kids are up to their old tricks. We're talking barbed wire, demogorgons on fire, ...

As we age, the human brain rewires itself. The process happens in distinct phases, or “epochs,” according to new research, as the structure of our neural networks changes and our brains reconfigure ...

Danish researchers were examining the use of medications during and after pregnancy when they noticed a clear trend: The number of women using weight-loss drugs like Ozempic and Wegovy soon after ...

Researchers from Boston University School of Medicine looked at data from the 'Framingham Heart Study', which began in 1948 and recruited men and women from the town of Framingham in the US state of ...

It hasn't exactly been smooth sailing, but - after what they endured last season - most Chicago Bears fans would have readily accepted a 5-3 record with a home game against the lowly New York Giants ...

ModeLock PLM1, PLM2, and PLM3 Saves the User’s Current Drive Mode Settings for the Next Time the Vehicle is Started CHICAGO, Oct. 23, 2025 – Mid City Engineering, a leading provider of innovative ...

EDITOR’S NOTE: The views expressed in this commentary are solely those of the writers. CNN is showcasing the work of The Conversation, a collaboration between journalists and academics to provide news ...

Bristol Myers Squibb has ended its R&D losing streak with a hit on one of the dual primary endpoints in a phase 3 multiple myeloma trial. But with the study continuing to evaluate the other primary ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...